OncoMatch/Clinical Trials/NCT06758037
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy
Is NCT06758037 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Drug therapy for dlbcl.
Treatment: Drug therapy — To explore the application of HiR (Zebtorizumab, Lenalidomide) + X (targeted drug) guided by NGS molecular typing, the aim is to assess the therapeutic efficacy and safety in newly diagnosed unfit or frail elderly patients with DLBCL aged ≥70 years, and to investigate the genetic subtypes that may benefit from HiR-X.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20-positive)
Histologically confirmed CD20-positive diffuse large B-cell lymphoma
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Lab requirements
Kidney function
creatinine < 2 times the upper limit of normal (uln)
Liver function
alt (alanine aminotransferase) / ast (aspartate aminotransferase) < 2.5 x uln; total bilirubin < 2 x uln
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06758037 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MS4A1?
Yes, MS4A1 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger and at least 70 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify